Trovagene Company Profile (NASDAQ:TROV)

Analyst Ratings

Consensus Ratings for Trovagene (NASDAQ:TROV) (?)
Ratings Breakdown: 6 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $7.20 (35.08% upside)

Analysts' Ratings History for Trovagene (NASDAQ:TROV)
Show:
DateFirmActionRatingPrice TargetActions
7/6/2016Maxim GroupInitiated CoverageBuy$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2016Piper Jaffray Cos.Reiterated RatingHold$8.00 -> $5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2016Leerink SwannReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/11/2016Cantor FitzgeraldReiterated RatingHold$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/28/2016ArgusDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/29/2016Avondale PartnersReiterated RatingMarket Perform$6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/11/2016Janney Montgomery ScottDowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for Trovagene (NASDAQ:TROV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/10/2016Q116($0.29)($0.36)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q415($0.25)($0.26)$100.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.24)($0.41)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2015($0.23)($0.24)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015Q414($0.26)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q3 14($0.25)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014($0.24)($0.18)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014($0.23)($0.17)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/17/2014Q413($0.19)($0.05)$0.15 million$0.05 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2013Q313($0.22)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2013Q213($0.15)($0.34)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2013Q113($0.09)($0.07)$0.03 million$0.12 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Trovagene (NASDAQ:TROV)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.32)($0.32)($0.32)
Q2 20162($0.33)($0.33)($0.33)
Q3 20162($0.38)($0.37)($0.38)
Q4 20161($0.40)($0.40)($0.40)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Trovagene (NASDAQ:TROV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Trovagene (NASDAQ:TROV)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
8/12/2015Antonius SchuhCEOBuy20,000$5.45$109,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2015Stanley TennantDirectorBuy10,000$6.06$60,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2015Steve ZaniboniCFOBuy15,000$5.43$81,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/17/2015Bridger Management, LlcMajor ShareholderBuy140,000$8.75$1,225,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2015Bridger Management, LlcMajor ShareholderBuy300,000$6.90$2,070,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/27/2015Bridger Management, LlcMajor ShareholderBuy263,286$5.36$1,411,212.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/6/2015Bridger Management, LlcMajor ShareholderBuy444,444$4.50$1,999,998.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2014Steve ZaniboniCFOBuy6,329$3.95$24,999.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013Thomas Phd AdamsDirectorSell19,200$8.19$157,248.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/30/2012Stanley TennantDirectorBuy25,000$4.82$120,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2012Gabriel CerroneDirectorBuy7,800$2.35$18,330.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/16/2012Gabriel CerroneDirectorBuy15,000$2.24$33,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Trovagene (NASDAQ:TROV)
DateHeadline
07/26/16 07:24 PMWill TrovaGene, Inc. (NASDAQ:TROV) Surprise Analysts? - Investor Newswire
07/26/16 07:24 PMTrovaGene Inc.: Trovagene Schedules Release of Second Quarter 2016 Financial Results and Investor Conference Call - The Wall Street Transcript
07/26/16 03:32 PMTROVAGENE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obliga -
07/26/16 10:28 AMDiagnostic Performance of Urinary EGFR Testing in Lung Cancer Patients Published in Journal of Thoracic Oncology
07/26/16 07:58 AMTrovagene Schedules Release of Second Quarter 2016 Financial Results and Investor Conference Call - [at noodls] - SAN DIEGO, July 26, 2016/PRNewswire / -- Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, announced today that it will report financial results for the ...
07/24/16 06:20 PMIs $12 Price Target Attainable For TrovaGene, Inc. (NASDAQ:TROV)? - Investor Newswire
07/22/16 09:49 AMTrovaGene, Inc. (NASDAQ:TROV): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/20/16 07:56 PMIncreased Stock Volatility Watch: TrovaGene, Inc. (NASDAQ:TROV) - Engelwood Daily
07/20/16 09:46 AMEarnings Focus and Crowd Sourced Sentiment Review for TrovaGene, Inc. (NASDAQ:TROV) - TGP
07/20/16 09:46 AMEquity Roundup: Stock Performance Focus on TrovaGene, Inc. (NASDAQ:TROV) - Press Telegraph
07/20/16 09:46 AMTrovaGene Inc Stock Momentum at Critical Inflection Point - CML News
07/18/16 08:13 AMAre Analysts Bullish TrovaGene Inc (NASDAQ:TROV) After Last Week? - Consumer Eagle
07/18/16 08:13 AMStrong Sell Calls For TrovaGene, Inc. (NASDAQ:TROV) At 0 - Investor Newswire
07/16/16 10:04 AMTrovaGene, Inc. (NASDAQ:TROV) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/16/16 10:04 AMShares Experiencing a Downtrend: TrovaGene, Inc. (NASDAQ:TROV) - TGP
07/15/16 12:13 PMTrovagene : and University of Michigan Enter into Collaboration for Monitoring and Early Detection of Pancreatic Cancer
07/14/16 10:32 AMAnalyst Target and Average Rating Watch: TrovaGene, Inc. (NASDAQ:TROV) - Press Telegraph
07/14/16 10:32 AMHC Stocks Growth: TrovaGene Inc (NASDAQ:TROV), Prima BioMed Ltd (ADR) (NASDAQ:PBMD) - share market updates (press release)
07/14/16 10:32 AMTrovaGene Inc Declines A lot Today, Is Now One of The Worst Performer - Consumer Eagle
07/14/16 10:32 AMTrovagene Inc (NASDAQ:TROV) Stock Price Loses While Sentiment Improves - Consumer Eagle
07/13/16 05:05 PMTrovaGene Inks Partnership with USC Norris Cancer Center -
07/13/16 09:46 AMTrovagene (TROV) to Collaborate with USC Norris to Standardize Use of ctDNA Liquid Biopsy Tests
07/12/16 07:08 PMTrovogene Announces Another Collaboration, This One With USC
07/12/16 07:08 PMTrovagene and USC Norris Comprehensive Cancer Center Collaborate to Standardize the Use of Trovera™ ctDNA Liquid Biopsy Tests in Patient Care
07/12/16 11:12 AMTrovaGene Inc (NASDAQ:TROV)'s Company Shares Increased 4.71% After High Volatility - Press Telegraph
07/12/16 11:12 AMTrovaGene Inc.: Trovagene and USC Norris Comprehensive Cancer Center Collaborate to Standardize the Use of ... - The Wall Street Transcript
07/11/16 06:46 PMIs $12 Within Reach For TrovaGene, Inc. (NASDAQ:TROV)? - Investor Newswire
07/11/16 06:46 PMStock Volatility Focus for: TrovaGene, Inc. (NASDAQ:TROV) - Engelwood Daily
07/11/16 06:46 PM/CORRECTION -- Trovagene, Inc./ - Yahoo Finance
07/11/16 10:03 AM/C O R R E C T I O N -- Trovagene, Inc./ - [at noodls] - In the news release, Trovagene to Present at the 2nd Annual Cantor Fitzgerald Healthcare Conference, issued 05-Jul-2016by Trovagene, Inc. over PR Newswire, we are advised by the company that the second ...
07/11/16 09:45 AMTROVAGENE, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
07/09/16 06:07 PMWere Analysts Bullish TrovaGene Inc (NASDAQ:TROV) This Week? - Engelwood Daily
07/09/16 06:07 PMTrovaGene, Inc. Upside Stock Momentum at Extreme Strength - CML News
07/08/16 09:44 AMGlobal Cell-Free DNA (cfDNA) Testing Market 2016 Analysis and Forecasts to 2020
07/07/16 06:58 PMTrovagene, University of Michigan to Collaborate on Test for Early Detection of Pancreatic Cancer
07/07/16 09:38 AMCompany Stock Focus for TrovaGene, Inc. (NASDAQ:TROV): Which Way Will Shares Head? - Press Telegraph
07/07/16 04:57 AMCoverage initiated on TrovaGene by Maxim Group -
07/06/16 07:21 PMTrovagene to Present at the 2nd Annual Cantor Fitzgerald Healthcare Conference - PR Newswire (press release)
07/06/16 09:51 AMTROVAGENE, INC. Files SEC form 8-K, Other Events -
07/06/16 09:21 AMTrovagene and University of Michigan Enter into Collaboration for Monitoring and Early Detection of Pancreatic Cancer - [at noodls] - SAN DIEGO, July 6, 2016/PRNewswire / -- Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, today announced the initiation of a multi-phased collaborative ...
07/05/16 06:41 PMTrovagene to Present at the 2nd Annual Cantor Fitzgerald Healthcare Conference - [at noodls] - SAN DIEGO, July 5, 2016/PRNewswire / -- Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, today announced that its Chief Executive Officer, Bill Welch, ...
07/05/16 08:02 AMShare Performance Recap for: TrovaGene, Inc. (NASDAQ:TROV) - Press Telegraph
07/05/16 08:02 AMBroker Outlook For The Week Ahead TrovaGene, Inc. (TROV) - Fiscal Standard
06/30/16 09:36 AMNew Market Research Report: TrovaGene, Inc. (TROV) - Financial and Strategic SWOT Analysis Review
06/27/16 07:46 AMStrong Sell Calls Recommendations For TrovaGene, Inc. (NASDAQ:TROV) At 0 - Investor Newswire
06/27/16 07:46 AMTrovaGene, Inc. (TROV) Broker Price Targets For The Coming Week - Fiscal Standard
06/24/16 06:55 PMTrovaGene, Inc. (NASDAQ:TROV) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 04:48 PMETF’s with exposure to TrovaGene, Inc. : June 24, 2016 -
06/23/16 09:28 AMTrovaGene, Inc. (NasdaqCM:TROV) Stock Momentum Hits Weakness - CML News
06/20/16 06:26 PMStrong Buy Calls Count For TrovaGene, Inc. (NASDAQ:TROV) At 1 - Investor Newswire

Social

About Trovagene

Trovagene logoTrovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: TROV
  • CUSIP:
Key Metrics:
  • Previous Close: $5.33
  • 50 Day Moving Average: $4.7534
  • 200 Day Moving Average: $4.7667
  • P/E Ratio: N/A
  • P/E Growth: 0.0000
  • Market Cap: $163.64M
  • Beta: -0.96
  • Current Year EPS Consensus Estimate: $-1.44 EPS
  • Next Year EPS Consensus Estimate: $-0.64 EPS
Additional Links:
Trovagene (NASDAQ:TROV) Chart for Wednesday, July, 27, 2016